Market research
V3V.F VITA 34 AG
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 47M
- P/E ratio
- Not available
- Analyst target
- 6.5
- Dividend yield
- Not available
- Beta
- 0.64
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- ISIN
- DE000A0BL849
- Market cap
- 47M
- P/E ratio
- Not available
- Analyst target
- 6.5
- Dividend yield
- Not available
- Beta
- 0.64
About
About VITA 34 AG
FamiCord AG engages in the collection, processing, storage, and distribution of cells, tissues, blood, and blood components for medical applications in Germany, Poland, Switzerland, Portugal, and internationally. The company operates through Subgroup Vita 34 And Subgroup PBKM segments. It produces and develops advanced therapies, genetic tests, and analyses for third parties. The company also engages in the development and manufacture of cell and tissue-based products and pharmaceuticals, including the production of viral vectors or comparable products. In addition, it engages in research and development, storage, and cryopreservation of sperm and oocytes for use in reproductive medicine; and the manufacturing and distribution of medical devices. The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is headquartered in Leipzig, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the V3V.F discussion.
5 years, 6 months ago
VITA 34 AG is currently in a long term uptrend where the price is trading 7.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.
VITA 34 AG's total revenue rose by 5.8% to $5M since the same quarter in the previous year.
Its net income has increased by 443.8% to $745K since the same quarter in the previous year.
Finally, its free cash flow fell by 55.0% to $691K since the same quarter in the previous year.
Based on the above factors, VITA 34 AG gets an overall score of 4/5.